Larry Vernetti, Ph.D.
|Ph.D. in Toxicology, University of Arizona|
The focus of my research is developing early in vitro safety assessment and in vitro ADME models to identify risky compound candidates and allowing the drug developer to focus on fewer but more likely to succeed candidates. An important part of this research is the identification of the molecular mechanism of toxicity (MOA) within the cell, and then understanding how this can be used to predict target organ toxicity. The need for such an application is clear just by considering liver toxicity as an example. Despite decades of extensive animal testing, only half of the pharmaceutics which eventually produced clinical liver toxicity showed evidence of liver damage during animal trials. Bridging this gap is a necessary step forward to developing safer and effective drugs.
Skrypnyk NI, Sanker S, Brilli-Skvarca L, Novitskaya T, Woods C, Chiba T, Patel K, Goldberg ND, McDermott L, Vinson PN, Calcutt MW, Huryn DM,Vernetti LA, Vogt A, Hukriede N, de Caestecker MP (2015) Delayed treatment with PTBA analogs reduces post injury renal fibrosis after kidney injury Am J Physiol Renal Physiol. [Epub ahead of print]
Vernetti LA, Senutovitch N, Boltz R, DeBiasio R, Ying Shun T, Gough A, Taylor DL (2015). A human liver microphysiology platform for investigating physiology, drug safety, and disease models Exp Biol Med (Maywood). 241(1):101-14.
Senutovitch N, Vernetti L, Boltz R, DeBiasio R, Gough A, Taylor DL (2015) Fluorescent protein biosensors applied to microphysiological systems Exp Biol Med (Maywood) 240(6): 795-808.